BioCentury
ARTICLE | Company News

Cytokinetics, Astellas deal

January 5, 2015 8:00 AM UTC

The companies added the development of CK-2127107 for spinal muscular atrophy (SMA) and other neuromuscular indications to a 2013 deal to develop and commercialize skeletal muscle activators to treat diseases and conditions involving muscle weakness. The companies have also extended their research program through 2016 to discover skeletal sarcomere activators (see BioCentury, July 1, 2013). ...